ストックスクリーナーアプリを入手
12.92
10.28%
-1.48
前日終値:
$14.40
開ける：
$14.41
24時間の取引高:
315.41K
Relative Volume:
0.87
時価総額：
$434.03M
収益：
-
当期純損益:
$-47.20M
株価収益率:
-8.254
EPS:
-1.5653
ネットキャッシュフロー:
$-43.65M
1週間 パフォーマンス:
-9.46%
1か月 パフォーマンス:
+3.03%
6か月 パフォーマンス:
+19.85%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$12.76
$14.95
1週間の範囲:
$12.76
$15.19
52週間の値動き範囲:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
MBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
12.92 | 489.46M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-15 | 再開されました | Jefferies | Buy |
| 2025-08-05 | 開始されました | Mizuho | Outperform |
| 2025-07-16 | 開始されました | Oppenheimer | Outperform |
| 2025-04-10 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
すべてを表示
Mbx Biosciences Inc (MBX) 最新ニュース
What is MBX Biosciences Inc.’s book value per share2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - khodrobank.com
What’s the recovery path for long term holders of MBX Biosciences Inc.Trade Risk Summary & Weekly High Potential Alerts - Newser
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity - MarketScreener
MBX Biosciences Begins Phase 1 Trial for Obesity Drug - TipRanks
MBX Biosciences begins phase 1 trial of obesity treatment candidate - Investing.com
First-Ever Monthly GLP-1/GIP Obesity Drug Enters Clinical Trials: MBX Biosciences' Novel Treatment Begins Testing - Stock Titan
Identifying reversal signals in MBX Biosciences Inc.Weekly Earnings Recap & AI Powered Buy/Sell Recommendations - Newser
Is MBX Biosciences Inc. forming a reversal patternPortfolio Gains Summary & Reliable Price Breakout Alerts - Newser
How to escape a deep drawdown in MBX Biosciences Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Momentum Traders Eye MBX Biosciences Inc. for Quick BouncePortfolio Profit Report & Risk Managed Trade Strategies - beatles.ru
Will MBX Biosciences Inc. rebound enough to break evenJuly 2025 Fed Impact & Low Drawdown Investment Ideas - Newser
How hedge fund analytics apply to MBX Biosciences Inc. stockJuly 2025 Technicals & AI Driven Price Forecasts - Newser
Risk adjusted return profile for MBX Biosciences Inc. analyzedDollar Strength & Community Driven Trade Alerts - Newser
Is MBX Biosciences Inc. still worth holding after the dipGold Moves & Fast Entry Momentum Trade Alerts - Newser
Does MBX Biosciences Inc. meet Warren Buffett’s criteria2025 Macro Impact & Short-Term High Return Ideas - khodrobank.com
Technical analysis overview for MBX Biosciences Inc. stockMarket Activity Report & Advanced Swing Trade Entry Plans - Newser
How does MBX Biosciences Inc. compare to its peersLayoff News & AI Driven Stock Price Forecasts - khodrobank.com
Smart tools for monitoring MBX Biosciences Inc.’s price action2025 Market Trends & Detailed Earnings Play Strategies - Newser
What technical models suggest about MBX Biosciences Inc.’s comeback2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Why MBX Biosciences Inc. is moving todayEarnings Growth Report & Low Drawdown Investment Ideas - Newser
Buyout Rumor: Is MBX Biosciences Inc. trading at a discountJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - khodrobank.com
Using portfolio simulators with MBX Biosciences Inc. includedJuly 2025 Highlights & Fast Entry High Yield Tips - Newser
MBX Biosciences Inc. stock daily chart insightsJuly 2025 Breakouts & Free Community Consensus Stock Picks - Newser
What’s the beta of MBX Biosciences Inc. stockPortfolio Return Summary & Daily Profit Maximizing Tips - khodrobank.com
MBX Awaits Value-Creating Milestones, With Phase II Hypoparathyroidism Data Due Any Day - insights.citeline.com
Does MBX Biosciences Inc. show high probability of reboundWeekly Earnings Recap & Community Verified Trade Signals - Newser
What high frequency data says about MBX Biosciences Inc.2025 Earnings Impact & Short-Term High Return Ideas - Newser
Evaluating MBX Biosciences Inc. with trendline analysis2025 Market Overview & Long-Term Growth Stock Strategies - Newser
MBX Biosciences Inc. stock retracement – recovery analysis2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
MBX Biosciences Inc. stock prediction for this weekMarket Activity Recap & Long-Term Growth Portfolio Plans - Newser
How to recover losses in MBX Biosciences Inc. stockJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - Newser
Volatility clustering patterns for MBX Biosciences Inc.July 2025 Macro Moves & Long-Term Growth Stock Strategies - Newser
Using economic indicators to assess MBX Biosciences Inc. potentialWatch List & Real-Time Market Sentiment Reports - Newser
Applying Wyckoff theory to MBX Biosciences Inc. stockTrade Ideas & Scalable Portfolio Growth Methods - Newser
Mbx Biosciences Inc (MBX) 財務データ
収益
当期純利益
現金流量
EPS
Mbx Biosciences Inc (MBX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| GORDON CARL L | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| ORBIMED ADVISORS LLC | Director |
Feb 18 '25 |
Buy |
10.84 |
143,170 |
1,551,963 |
3,255,000 |
| ORBIMED ADVISORS LLC | Director |
Feb 14 '25 |
Buy |
9.87 |
47,502 |
468,793 |
3,205,930 |
| Hawryluk P. Kent | President & CEO |
Feb 04 '25 |
Buy |
10.69 |
50,000 |
534,500 |
448,277 |
| Mathers Edward T | Director |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| BASKETT FOREST | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Behbahani Ali | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Chang Carmen | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Florence Anthony A. Jr. | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
1.75%
1.11%
大文字化:
|
ボリューム (24 時間):